Brookstone Capital Management Sells 359 Shares of Cencora, Inc. $COR

Brookstone Capital Management decreased its position in shares of Cencora, Inc. (NYSE:COR) by 9.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,545 shares of the company’s stock after selling 359 shares during the quarter. Brookstone Capital Management’s holdings in Cencora were worth $1,063,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in COR. Invesco Ltd. boosted its position in Cencora by 42.1% during the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after purchasing an additional 1,364,433 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Cencora by 4,459.6% during the first quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after purchasing an additional 975,362 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Cencora by 8.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after purchasing an additional 787,858 shares in the last quarter. Nuveen LLC bought a new stake in Cencora during the first quarter valued at about $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec boosted its position in Cencora by 144.4% during the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock valued at $206,641,000 after purchasing an additional 439,008 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $333.02 on Friday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The company has a market cap of $64.56 billion, a PE ratio of 34.26, a P/E/G ratio of 1.55 and a beta of 0.63. The business has a 50-day simple moving average of $304.09 and a two-hundred day simple moving average of $295.02. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $334.34.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. During the same period last year, the business posted $3.34 earnings per share. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio (DPR) is presently 22.63%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on COR. Morgan Stanley set a $330.00 price objective on Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Wells Fargo & Company raised their price target on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Evercore ISI set a $340.00 price target on Cencora in a report on Wednesday, October 8th. Finally, Mizuho raised their price target on Cencora from $316.00 to $334.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $324.91.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.